MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Launched by AGENDIA · Feb 10, 2017
Trial Information
Current as of May 03, 2025
Recruiting
Keywords
ClinConnect Summary
The FLEX Registry is a clinical trial aimed at studying how specific gene tests, called MammaPrint® and BluePrint, can help doctors understand breast cancer better. This trial is for patients with early to middle-stage breast cancer (stages I to III) who are undergoing testing on their primary tumor. The goal is to collect information that can lead to new insights into breast cancer treatment and improve patient care.
To participate in this trial, patients must be diagnosed with a new breast cancer tumor and agree to take part by signing an informed consent form. Those with metastatic (spread to other parts of the body) or recurrent breast cancer, or those with very early-stage cancer (stage 0), are not eligible. If you join the trial, you can expect to undergo the MammaPrint® and BluePrint tests, which help determine the best treatment options based on your tumor's gene activity. This study is currently recruiting participants, and it aims to make it easier to add new areas of focus as the research progresses.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Stage I, II, or III patients who receive MammaPrint, with or without BluePrint testing (male or female)
- • Informed consent form signed on the same day or before enrollment
- • New primary lesion
- Exclusion Criteria:
- • Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria
- • Metastatic disease
- • Recurrent disease
- • Stage 0 disease
About Agendia
Agendia is a leading molecular diagnostics company specializing in personalized medicine for cancer patients. With a strong focus on breast cancer, Agendia develops innovative genomic tests that provide critical insights into tumor biology, enabling oncologists to make informed treatment decisions. The company is committed to advancing cancer research through rigorous clinical trials and collaboration with healthcare professionals, ultimately aiming to improve patient outcomes and quality of life. Agendia's expertise in genomic profiling positions it at the forefront of precision oncology, driving advancements that empower patients and clinicians alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
New Orleans, Louisiana, United States
Buffalo, New York, United States
Saint Louis, Missouri, United States
Amarillo, Texas, United States
Seattle, Washington, United States
Anchorage, Alaska, United States
Chicago, Illinois, United States
Syracuse, New York, United States
Seattle, Washington, United States
Clearwater, Florida, United States
Elk Grove Village, Illinois, United States
Redding, California, United States
Atlantis, Florida, United States
Palm Springs, California, United States
Lakeland, Florida, United States
Mineola, New York, United States
Decatur, Georgia, United States
Akron, Ohio, United States
Bethlehem, Pennsylvania, United States
Tampa, Florida, United States
Aurora, Colorado, United States
Fort Worth, Texas, United States
Baltimore, Maryland, United States
Portland, Oregon, United States
Jacksonville, Florida, United States
Aurora, Colorado, United States
Columbia, Missouri, United States
Langhorne, Pennsylvania, United States
Thunder Bay, Ontario, Canada
Miami, Florida, United States
Columbia, Maryland, United States
Nashville, Tennessee, United States
Savannah, Georgia, United States
Shreveport, Louisiana, United States
Albany, New York, United States
Lansing, Michigan, United States
Tel Aviv, , Israel
Flower Mound, Texas, United States
Tyler, Texas, United States
Pittsburgh, Pennsylvania, United States
Atlanta, Georgia, United States
Mount Vernon, Washington, United States
Dallas, Texas, United States
Lawton, Oklahoma, United States
Atlanta, Georgia, United States
Houston, Texas, United States
Eugene, Oregon, United States
Grapevine, Texas, United States
Winter Haven, Florida, United States
Bedford, Texas, United States
Portland, Oregon, United States
Rockledge, Florida, United States
Tucson, Arizona, United States
Sugar Land, Texas, United States
Denver, Colorado, United States
Waco, Texas, United States
Germantown, Tennessee, United States
Springfield, Massachusetts, United States
Southfield, Michigan, United States
Milwaukee, Wisconsin, United States
Longview, Texas, United States
Pittsburgh, Pennsylvania, United States
Miami, Florida, United States
Cincinnati, Ohio, United States
Minneapolis, Minnesota, United States
Daytona Beach, Florida, United States
Carrollton, Texas, United States
Plano, Texas, United States
San Antonio, Texas, United States
Dallas, Texas, United States
Birmingham, Alabama, United States
San Francisco, California, United States
Van Nuys, California, United States
Lakewood, Colorado, United States
Vail, Colorado, United States
Waterbury, Connecticut, United States
Newark, Delaware, United States
Atlantis, Florida, United States
Boca Raton, Florida, United States
Jacksonville, Florida, United States
Jacksonville, Florida, United States
Tampa, Florida, United States
Albany, Georgia, United States
Brunswick, Georgia, United States
Tifton, Georgia, United States
Hoffman Estates, Illinois, United States
Oak Lawn, Illinois, United States
Fort Wayne, Indiana, United States
Bethesda, Maryland, United States
Brandywine, Maryland, United States
Clinton, Maryland, United States
Cumberland, Maryland, United States
Frederick, Maryland, United States
Rockville, Maryland, United States
Silver Spring, Maryland, United States
Grosse Pointe Woods, Michigan, United States
Troy, Michigan, United States
Binghamton, New York, United States
Lake Success, New York, United States
Mount Kisco, New York, United States
Nyack, New York, United States
Rochester, New York, United States
Tarrytown, New York, United States
Cincinnati, Ohio, United States
Horsham, Pennsylvania, United States
Sellersville, Pennsylvania, United States
Charleston, South Carolina, United States
Georgetown, South Carolina, United States
Allen, Texas, United States
Corpus Christi, Texas, United States
Dallas, Texas, United States
Denton, Texas, United States
Katy, Texas, United States
League City, Texas, United States
Lubbock, Texas, United States
Mckinney, Texas, United States
Plano, Texas, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
Webster, Texas, United States
Ogden, Utah, United States
Athens, , Greece
Austin, Texas, United States
Broomall, Pennsylvania, United States
Phoenix, Arizona, United States
Bakersfield, California, United States
Portland, Maine, United States
Annapolis, Maryland, United States
Royal Oak, Michigan, United States
New York, New York, United States
Houston, Texas, United States
Brampton, Ontario, Canada
Patients applied
Trial Officials
William Audeh, MD
Study Director
Agendia, Inc.
Joyce O'Shaughnessy, MD
Principal Investigator
Texas Oncology - Baylor Charles A. Sammons Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials